NCT02525380View on ClinicalTrials.gov

Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma

PHASE4UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

November 30, 2017

Study Completion Date

August 31, 2018

Conditions
Hepatocellular Carcinoma
Interventions
PROCEDURE

Device(DC Bead)

Doxorubicin-Eluting-Bead Embolization (DEBDOX), DC Bead are a novel drug delivery embolization system

Trial Locations (1)

"ASI

Seoul National University, Seoul

Sponsors

Collaborators (1)

BTG International Inc.
All Listed Sponsors
collaborator

BTG International Inc.

OTHER

lead

Seoul National University Hospital

OTHER

NCT02525380 - Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter